Fig. 1

Cyclophosphamide vs. rituximab

CYC: cyclophosphamide; RTX: Rituximab; SLE: systemic lupus erythematosus; AAV: anti-neutrophilic cytoplasmic antibody-associated vasculitis

Fig. 1 shows clinicians’ responses when asked about their approximate preference for CYC or RTX as the first choice of SLE and/or AAV induction treatment